Ares Life Sciences to Acquire Antigen Laboratories, Inc., in the United States

GENEVA, SWITZERLAND–(Marketwired – Apr 15, 2013) –
Ares Life Sciences, a healthcare-focused
investment group, announced today that it has signed a definitive
agreement to acquire 100% of the share capital of Planet
Biopharmaceuticals, Inc., including its wholly owned subsidiary
Antigen Laboratories, Inc., a producer of allergen extracts, who
works closely with the ENT (Ear, Nose and Throat) specialist
community in the United States. Closing of the transaction is
subject to certain closing conditions.

Ares recently signed an agreement to acquire Greer Laboratories,
Inc. a leader in U.S. allergy immunotherapy (AIT) market. The
acquisition of Antigen Laboratories is a continuation of Ares’
strategic focus on the U.S. AIT market. It is also the majority
shareholder of the French based Stallergenes S.A., a pioneer and
leader in immunotherapy treatments by sublingual administration.
Ares believes there is significant growth potential in the AIT
business globally, particularly in the US which currently only
represents 10% of the European market and is expected to grow
significantly over the next few years.

Jacques Theurillat, CEO of Ares Life Sciences, commented: “As an
FDA licensed manufacturer, Antigen has one of the most
comprehensive offerings of allergenic extracts in the United States
and has a long track record of serving the needs for the ENT
specialists. We view the acquisition of Antigen as very
complementary to our other investments in the allergy market.”

Theron E. Odlaug, Planet Biopharmaceuticals Executive Chairman
and CEO, commented, “We are looking forward to becoming a member of
the Ares portfolio of life science companies and the resources they
will provide to help us continue to grow.”

The U.S. Allergy Business

It is estimated that 10% to 30% of the global population suffers
from allergic rhinitis.
1In the United States, more than 40 million Americans
suffer from allergic diseases
2, approximately half of whom are allergic to grass
pollen. The current standard of care in allergy immunotherapy
involves multiple injections of allergens which are prepared from
bulk extract material. These injections are performed in a
supervised medical setting. Currently, approximately 2 to 3 million
Americans in the U.S. are treated with subcutaneous immunotherapy

About Antigen Laboratories, Inc.

Antigen Laboratories was founded in 1968 and has been providing
quality allergenic extracts and ancillary supplies to the allergy
profession for decades. For more information, visit

About Ares Life Sciences

Ares Life Sciences is a healthcare-focused investment group,
whose financial backer is the Bertarelli family. Its strategy is to
focus on key life sciences sectors, mainly: pharmaceuticals and
biotechnology, medical diagnostics, and medical technology. Ares
Life Sciences has a long-term view on investments and a core
element of its investment strategy is to make available to its
portfolio companies the collective experience and network of its
team in the healthcare sector. Ares Life Sciences’ portfolio
currently includes investments in Stallergenes, Euromedic, and


1. American Academy of Allergy Asthma and Immunology,
Accessed March 7, 2013

2. Something in the air: airborne allergens. Pamphlet from
Literature and Periodicals Library provided by
Published March 1993. Accessed February 13, 2013.

3. Allergen Immunotherapy for Allergic Rhinitis and Asthma. Cox
L, Atwater S. Allergy Immunotherapy: a payer’s perspective. Drug
Benefits Trends. March 2008; (20 Supplement A, page 5)

Dynamics Group

Christophe Lamps

+41 22 308 62 22 or Mob: +41 79 476 26 87

If you enjoyed this post, please consider leaving a comment or subscribing to the RSS feed to have future articles delivered to your feed reader.